Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RCFPY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BL-M11D1
|
|||||
| Synonyms |
BL M11D1; BL-M11D1; BLM11D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Baili Pharmaceutical Co., Ltd.; Chengdu Bailidote Biological Pharmaceutical Co., Ltd.; Sichuan Biokin Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
10
|
|||||
| Antibody Name |
Gemtuzumab
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
Camptothecin analogue ED04
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Gly-Mal-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
brengitecan
|
|||||
